Work

Leukemia Stem Cell Marker CD123 (IL-3R alpha) Predicts Minimal Residual Disease and Relapse, Providing a Valid Target For SL-101 In Acute Myeloid Leukemia With FLT3-ITD Mutations

Year: 2013

Type: article

Study design: Observational Study

Source: Blood

DOI: 10.1182/blood.v122.21.359.359

Authors: Lina Han, Jeffrey L. Jorgensen, Sa A. Wang, Xuelin Huang, Graciela M Nogueras González, Christopher Brooks, Eric Rowinsky, Mark Levis, Jin Zhou, Stefan O. Ciurea, Gheath Alatrash, Jorge E. Cortes, Hagop M. Kantarjian, Michael Andreeff, Farhad Ravandi, Marina Konopleva

Institutions: The University of Texas MD Anderson Cancer Center, Stemline Therapeutics (United States), Johns Hopkins University, Harbin Medical University, First Affiliated Hospital of Harbin Medical University

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2411745199

FWCI: 1.068

Cites:

Cited by: 14

Related to: 10